Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06254209
Other study ID # COS04
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 6, 2023
Est. completion date April 2024

Study information

Verified date February 2024
Source Nexira
Contact Damien Guillemet
Phone +33232831818
Email d.guillemet@nexira.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to evaluate the effects on the skin of 3 foods supplements compared to placebo after daily intake for 3 months in female subjects presenting healthy skin. Skin parameters measured are: the firmness of the skin and other biomechanical skin properties (elasticity, tonicity, density), cellulitis visibility, radiance complexion, skin condition (microrelief, skin barrier function and moisturizing)


Description:

Study design: Monocentric, randomized, double blind, placebo controlled, 3 groups in parallel.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy - Phototype II to IV (Fitzpatrick) - Visual skin radiance score (face) = 7 (0 to 9 points numeric scale) - Tactile skin firmness score (cheek) = 7 (0 to 9 points numeric scale) - Visual cellulite score (thigh) = 3 (0 to 9 points numeric scale) Exclusion Criteria: - Chronic pathology or systemic disorder - Subjects presenting imperfections on the test sites - Pregnant or who are planning to become pregnant - Medication or condition that may interfere with tested outcomes

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Botanicals extracts
Powder included in capsules for daily administration
Placebo
Maltodextrin included in capsules for daily administration

Locations

Country Name City State
France Intertek Paris

Sponsors (1)

Lead Sponsor Collaborator
Nexira

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Firmness of the skin Cutometry measurements using Cutometer (cheekbone) Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin elasticity and tonicity Cutometry measurements using the Cutometer (cheekbone) Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin density Ultrasound imaging device (lower cheek) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of fine lines visibility on face, assessed by panelist (trained technician) 10 points numeric scale: 0 (not visible) to 9 (highly visible) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of skin radiance of face, assessed by panelist (trained technician) 10 points numeric scale: 0 (dull) to 9 (radiant) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of nourishing aspect (hydration and quality aspect) of face, assessed by panelist (trained technician) 10 points numeric scale: 0 (malnourished) to 9 (nourished) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of skin firmness (tactile pinch of right cheek), assessed by panelist (trained technician) 10 points numeric scale: 0 (sagging) to 9 (firm) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of skin softness (tactile perception of right cheek), assessed by panelist (trained technician) 10 points numeric scale: 0 (rough) to 9 (soft) Day 0 (inclusion) and Day 84 (last visit)
Secondary Score of cellulite visibility (right thigh), assessed by panelist (trained technician) 10 points numeric scale: 0 (not visible) to 9 (highly visible) Day 0 (inclusion) and Day 84 (last visit)
Secondary Dimpled skin - volume (mm3) of humps and dimples Picture acquisition by fringe projection (on tight) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Dimpled skin - surface (mm2) of humps and dimples Picture acquisition by fringe projection (on tight) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin luminosity - CIELAB (L*a*b) Standardized pictures acquisitions (face) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin color texture - Haralick parameter (contrast & entropy - no unit) Standardized pictures acquisitions (face) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin specular reflectance (spectral reflectance - no unit) Standardized pictures acquisitions (face) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin roughness (mean height - µm) Standardized 3D pictures acquisitions (cheek) and software integration Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin barrier function (g/h/m²) Trans-epidermal water loss (forearm) Day 0 (inclusion) and Day 84 (last visit)
Secondary Skin moisture (%) Reflected electromagnetic probe (forearm) Day 0 (inclusion) and Day 84 (last visit)
Secondary Self perceived questionnaire (4 scales) Questionnaire (Satisfied, Somewhat satisfied, Somewhat unsatisfied, Unsatisfied) Day 0 (inclusion), Day 42 (intermediate) and Day 84 (last visit)
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1